Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Astrazeneca Plc (AZN)
NASDAQ:AZN
AZN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$62.75 - $87.68
Previous CloseN/A
Volume1.80M
Average Volume (3M)5.43M
Market Cap
$228.97B
Enterprise Value$229.41B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)32.4
Beta0.41
Next Earnings
Apr 29, 2025EPS Estimate
1.11Next Dividend Ex-Date
Feb 21, 2025Dividend Yield1.95%
Share Statistics
EPS (TTM)2.27
Shares Outstanding3,101,162,400
10 Day Avg. Volume6,440,443
30 Day Avg. Volume5,428,759
Standard Deviation0.06
R-Squared0.15
Alpha0.00464
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.60
Price to Cash Flow (P/CF)20.30
P/FCF Ratio28.50
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.23
Enterprise Value/Ebitda13.32
Forecast
1Y Price Target
$89.94Price Target Upside20.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company reported total revenues of $13.565bn, surpassing consensus estimates by 4%.
Oncology PortfolioThe oncology portfolio achieved multiple beats against consensus, with key products like Tagrisso, Lynparza, and Enhertu outperforming expectations.
Regulatory ApprovalThe FDA approved AZN's Datroway for HR+/HER2 negative/null breast cancer patients, marking a significant milestone with its first US approval.
Bears Say
Potential Financial RiskAstraZeneca faces a potential financial risk due to the notice regarding suspected unpaid importation taxes in China, totaling $900,000.
Regulatory RisksAstraZeneca received notice from Chinese authorities of a suspected unpaid importation tax of $0.9mn, related to allegations of illegal drug importation.
Revenue DeclineRevenues in China declined 3% year-over-year in the fourth quarter, influenced by lower demand for respiratory products due to seasonal dynamics.
---
Ownership Overview
―
Insiders
6.06% Mutual Funds
6.33% Other Institutional Investors
86.75% Public Companies and Individual Investors
AZN FAQ
What was Astrazeneca Plc’s price range in the past 12 months?
Astrazeneca Plc lowest stock price was $62.75 and its highest was $87.67 in the past 12 months.
What is Astrazeneca Plc’s market cap?
Astrazeneca Plc’s market cap is $228.97B.
When is Astrazeneca Plc’s upcoming earnings report date?
Astrazeneca Plc’s upcoming earnings report date is Apr 29, 2025 which is in 68 days.
How were Astrazeneca Plc’s earnings last quarter?
Astrazeneca Plc released its earnings results on Feb 06, 2025. The company reported $1.045 earnings per share for the quarter, beating the consensus estimate of $1.035 by $0.01.
Is Astrazeneca Plc overvalued?
According to Wall Street analysts Astrazeneca Plc’s price is currently Undervalued.
Does Astrazeneca Plc pay dividends?
Astrazeneca Plc pays a Semiannually dividend of $1.029 which represents an annual dividend yield of 1.95%. See more information on Astrazeneca Plc dividends here
What is Astrazeneca Plc’s EPS estimate?
Astrazeneca Plc’s EPS estimate is 1.11.
How many shares outstanding does Astrazeneca Plc have?
Astrazeneca Plc has 3,101,162,400 shares outstanding.
What happened to Astrazeneca Plc’s price movement after its last earnings report?
Astrazeneca Plc reported an EPS of $1.045 in its last earnings report, beating expectations of $1.035. Following the earnings report the stock price went up 2.002%.
Which hedge fund is a major shareholder of Astrazeneca Plc?
Currently, no hedge funds are holding shares in AZN
---
AstraZeneca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$89.94 (20.24% Upside)
$89.94 (20.24% Upside)
Blogger Sentiment
Bullish
AZN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.84%
12-Months-Change
Fundamentals
Return on Equity
17.60%
Trailing 12-Months
Asset Growth
2.88%
Trailing 12-Months
Company Description
Astrazeneca Plc
Founded in 1992, UK-based AstraZeneca Plc is a leading global pharmaceutical company, which is engaged in delivering life-changing medicines. The company produces and commercializes medicines for cancer, gastrointestinal, cardiovascular, neuroscience, oncology, respiratory and inflammation and other infectious diseases.
---
AZN Company Deck
---
AZN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects strong overall performance with significant revenue growth, successful product approvals, and strategic pipeline advancements. However, challenges in the China market, anticipated headwinds from VBP and IRA, and increased operating expenses highlight areas of concern. The sentiment is balanced between strong growth prospects and operational challenges.Read More>---
AZN Stock 12 Month Forecast
Average Price Target
$89.94
▲(20.24% Upside)
Technical Analysis
Best Analysts Covering AZN
1 Year
1 Year Success Rate
18/24 ratings generated profit
1 Year Average Return
+11.17%
reiterated a buy rating last month
Copying Sachin Jain's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +11.17% per trade.
---